Abstract
This report provides and in-depth analysis of the market for prescription
drugs used in the treatment of gastrointestinal (GI) disorders, such as nausea
and vomiting, heartburn, gastro-esophageal reflux disease (GERD), ulcer,
cancers of the GI tract (colorectal, esophageal, and gastric), Crohn's
disease, ulcerative colitis, irritable bowel syndrome (IBS), diverticular
disease, constipation, celiac disease, short bowel syndrome, diarrhea,
intestinal obstruction, and digestive enzyme disorders. For each major
segment, the analysis provides an overview of the diseases including
epidemiology, a detailed description of products on the market, products in
research and development, and market estimates and forecasts through 2010 by
drug type and by geographical market (U.S. and non-U.S). Competitive market
share information is also provided for 2005 and projected for 2010now and and
top drugs. The analysis includes market projections for:
- antiemetics,
- H2 receptorantagonists,
- proton pump inhibitors (PPIs),
- other antacid/antiulcer therapeutics,
- immunotherapy for GI cancers,
- chemotherapy for GI cancers,
- anti-inflammatories,
- anti-spasmodics,
- anti-infectives,
- enzymes, and
- several other miscellaneous GI drug categories
In addition to market data, the report includes current issues and trends
affecting the industry and what trends may arise in the future and profiles
the top competitors in the field.
View Cart
